AGLE
Income statement / Annual
Last year (2022), Aeglea BioTherapeutics, Inc.'s total revenue was $2.33 M,
a decrease of 87.57% from the previous year.
In 2022, Aeglea BioTherapeutics, Inc.'s net income was -$83.82 M.
See Aeglea BioTherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$2.33 M
|
$18.74 M
|
$0.00
|
$0.00
|
$3.89 M
|
$5.21 M
|
$4.63 M
|
$6.09 M
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$2.33 M |
$18.74 M |
$0.00 |
$0.00 |
$3.89 M |
$5.21 M |
$4.63 M |
$6.09 M |
$0.00 |
| Gross Profit Ratio |
1 |
1 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
| Research and Development
Expenses |
$58.58 M
|
$57.07 M
|
$59.64 M
|
$64.60 M
|
$36.72 M
|
$22.82 M
|
$18.14 M
|
$11.45 M
|
$6.83 M
|
| General & Administrative
Expenses |
$28.53 M
|
$27.32 M
|
$21.84 M
|
$15.73 M
|
$12.63 M
|
$10.07 M
|
$8.39 M
|
$5.95 M
|
$2.07 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$28.53 M
|
$27.32 M
|
$21.84 M
|
$15.73 M
|
$12.63 M
|
$10.07 M
|
$8.39 M
|
$5.95 M
|
$2.07 M
|
| Other Expenses |
-$7,000.00 |
-$122,000.00 |
-$5,000.00 |
-$63,000.00 |
-$57,000.00 |
-$42,000.00 |
-$36,000.00 |
-$2,000.00 |
$0.00 |
| Operating Expenses |
$87.11 M |
$84.39 M |
$81.48 M |
$80.33 M |
$49.35 M |
$32.88 M |
$26.53 M |
$17.40 M |
$8.90 M |
| Cost And Expenses |
$87.11 M |
$84.39 M |
$81.48 M |
$80.33 M |
$49.35 M |
$32.88 M |
$26.53 M |
$17.40 M |
$8.90 M |
| Interest Income |
$837,000.00 |
$111,000.00 |
$593,000.00 |
$2.14 M |
$1.17 M |
$482,000.00 |
$244,000.00 |
$22,000.00 |
$1,000.00 |
| Interest Expense |
$837,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.57 M
|
$1.58 M
|
$996,000.00
|
$418,000.00
|
$293,000.00
|
$249,000.00
|
$132,000.00
|
$89,000.00
|
$19,000.00
|
| EBITDA |
-$84.78 M
|
-$65.65 M
|
-$80.49 M
|
-$80.33 M
|
-$44.06 M
|
-$27.68 M
|
-$21.77 M
|
-$11.23 M
|
-$7.44 M
|
| EBITDA Ratio |
-36.4 |
-3.5 |
0 |
0 |
-11.33 |
-5.32 |
-4.7 |
-1.84 |
0 |
| Operating Income Ratio
|
-36.4
|
-3.5
|
0
|
0
|
-11.69
|
-5.32
|
-4.73
|
-1.86
|
0
|
| Total Other
Income/Expenses Net |
$830,000.00
|
-$11,000.00
|
$588,000.00
|
$2.08 M
|
-$57,000.00
|
-$42,000.00
|
-$36,000.00
|
$20,000.00
|
-$1.44 M
|
| Income Before Tax |
-$83.95 M |
-$65.66 M |
-$80.89 M |
-$78.25 M |
-$44.35 M |
-$27.24 M |
-$21.70 M |
-$11.30 M |
-$10.35 M |
| Income Before Tax Ratio
|
-36.05
|
-3.5
|
0
|
0
|
-11.41
|
-5.23
|
-4.69
|
-1.86
|
0
|
| Income Tax Expense |
-$136,000.00 |
$141,000.00 |
-$593,000.00 |
-$2.56 M |
-$57,000.00 |
-$731,000.00 |
-$244,000.00 |
-$22,000.00 |
$1.44 M |
| Net Income |
-$83.82 M |
-$65.80 M |
-$80.30 M |
-$75.69 M |
-$44.35 M |
-$27.24 M |
-$21.70 M |
-$11.30 M |
-$10.35 M |
| Net Income Ratio |
-35.99 |
-3.51 |
0 |
0 |
-11.41 |
-5.23 |
-4.69 |
-1.86 |
0 |
| EPS |
-24.86 |
-25.02 |
-37.61 |
-59.23 |
-53.25 |
-45.01 |
-55.4 |
-24.71 |
-37.93 |
| EPS Diluted |
-24.86 |
-25.02 |
-37.61 |
-59.23 |
-53.25 |
-45.01 |
-55.4 |
-24.71 |
-37.93 |
| Weighted Average Shares
Out |
$3.37 M
|
$2.63 M
|
$2.13 M
|
$1.28 M
|
$832,902.00
|
$605,127.00
|
$391,669.00
|
$457,193.00
|
$272,801.00
|
| Weighted Average Shares
Out Diluted |
$3.37 M
|
$2.63 M
|
$2.13 M
|
$1.28 M
|
$832,902.00
|
$605,127.00
|
$391,669.00
|
$457,193.00
|
$272,801.00
|
| Link |
|
|
|
|
|
|
|
|
|
